The Effect of Donepezil Treatment on Cardiovascular Mortality | Zendy

Sato K | Zendy; Urbano R | Zendy; Yu C | Zendy; Yamasaki F | Zendy; Sato T | Zendy; Jordan J | Zendy; Robertson D | Zendy; Diedrich A | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

The Effect of Donepezil Treatment on Cardiovascular Mortality

Author(s) -

Sato K,

Urbano R,

Yu C,

Yamasaki F,

Sato T,

Jordan J,

Robertson D,

Diedrich A

Publication year - 2010

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1038/clpt.2010.98

Subject(s) - donepezil , medicine , hazard ratio , confidence interval , dementia , acetylcholinesterase , vascular dementia , clinical pharmacology , prospective cohort study , rivastigmine , clinical trial , pharmacology , disease , biochemistry , chemistry , enzyme

The acetylcholinesterase inhibitor donepezil hydrochloride improves cognitive function in patients with Alzheimer's disease and vascular dementia. Given acetylcholine's important actions on the heart, we undertook a retrospective cohort investigation to assess whether donepezil usage affects cardiovascular mortality. In patients treated with donepezil, hazard ratios for total and cardiovascular mortality were 0.68 ( P = 0.045, 95% confidence interval 0.46–0.99) and 0.54 ( P = 0.042, 95% confidence interval 0.30–0.98), respectively. The apparent survival benefit in donepezil‐treated patients should not be overinterpreted. Prospective clinical trials are warranted. Clinical Pharmacology & Therapeutics (2010) 88 3, 335–338. doi: 10.1038/clpt.2010.98

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research